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Abstract
Certain higher vertebrates developed the ability to reverse muscle cell differentiation (dedifferentiation) as an additional
mechanism to regenerate muscle. Mammals, on the other hand, show limited ability to reverse muscle cell differentiation.
Myogenic Regulatory Factors (MRFs), MyoD, myogenin, Myf5 and Myf6 are basic-helix-loop-helix (bHLH) transcription
factors essential towards the regulation of myogenesis. Our current interest is to investigate whether down-regulation of
MRFs in terminally differentiated mouse myotubes can induce reversal of muscle cell differentiation. Results from this work
showed that reduction of myogenin levels in terminally differentiated mouse myotubes can reverse their differentiation
state. Down-regulation of myogenin in terminally differentiated mouse myotubes induces cellular cleavage into
mononucleated cells and cell cycle re-entry, as shown by re-initiation of DNA synthesis and increased cyclin D1 and
cyclin E2 levels. Finally, we provide evidence that down-regulation of myogenin causes cell cycle re-entry (via down-
regulation of MyoD) and cellularisation through separate pathways. These data reveal the important role of myogenin in
maintaining terminal muscle cell differentiation and point to a novel mechanism by which muscle cells could be re-
activated through its down-regulation.
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Introduction
Vertebrates like zebrafish and salamanders can display unique
regenerative abilities through dedifferentiation or differentiation of
precursor cells [1]. After injury, these vertebrates are able to
induce reversal of the differentiation state, which leads to a series
of events that aim to generate proliferating regenerative progenitor
cells with the ability to restore in a precise way the lost tissue
[1,2,3]. In addition, recent studies showed that terminally
differentiated mammalian muscle cells are capable to reverse their
differentiation state. The course of myogenesis is a well
characterized example of terminal differentiation. Myoblasts are
capable of proliferation and upon demand to form skeletal muscle,
they exit the cell cycle and through the activation of muscle-
specific transcription factors they fuse into multinucleated
terminally differentiated myotubes [4,5]. Some research groups
have attempted to induce dedifferentiation of muscle cells by
exogenous genes or chemicals. Mouse C2C12 myotubes treated
with limb regeneration extracts were able to induce myotubes to
reenter the cell cycle, exhibited reduced levels of muscle
differentiation proteins and cleaved to produce smaller myotubes
or proliferating mononucleated cells [6]. In another study,
combination of growth medium and ectopic msx1 expression
caused the reduction of muscle-specific proteins and the cleavage
of these myotubes into proliferating mononucleated cells that were
able to redifferentiate into muscle or trans-differentiate into
various cell types [7]. In a similar way, overexpression of Twist,
a nuclear basic helix-loop-helix (bHLH) transcription factor
known to inhibit muscle cell differentiation, in terminally
differentiated myotubes caused their cleavage to mononucleated
cells and re-entry to the cell cycle [8]. Moreover, microinjection of
Barx2 cDNA into immature myotubes derived from primary cells
led to cleavage and formation of mononucleated cells that were
able to proliferate [9]. Using a chemical approach, terminal
differentiated myotubes were incubated with a triazine compound.
Myotubes were cellularized into smaller myotubes or mononucle-
ated cells, which were able to survive and divide [10]. Similarly,
myoseverin a trisubstituted purine was shown to induce reversible
fission of multinucleated myotubes into mononucleated cells,
which were able to enter the cell cycle [11]. Recently, mammalian
skeletal muscle cells were induced to dedifferentiate into
proliferating mononuclear cells, after treatment with myoseverin
and temporary p21 suppression. These cells were further induced
to act as multipotent stromal cells by further treatment with the
small molecule, reversine (2-(4-morpholinoanilino)-6-cyclohexyla-
minopurine) and simple chemical modifications of the culture
media [12]. When cell cycle inhibitors, p21 and p27 were depleted
from terminal differentiated mouse myotubes, incomplete DNA
replication and apoptosis was observed. In contrast, when p21 and
p27 were depleted from quiescent, non-terminal differentiated
fibroblasts and muscle cells, DNA replication was fully recovered
and apoptosis was no longer observed. These cells were able to
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evidence for natural dedifferentiation of muscle cells, following
injury was reported by using a Cre/Lox-b-galactosidase system
[14,15].
Myogenic regulatory factors (MRFs), myogenin, MyoD, MRF4
(Myf6) and Myf5 are basic-helix-loop-helix (bHLH) transcription
factors that regulate myogenesis [16,17,18,19,20,21,22]. MyoD is
absent during G0 phase of the cell cycle, but is highly expressed
during mid-G1 phase and between S to M phase. Myf5 is highly
expressed during G0 and decreases during G1 phase [23]. MyoD
was found to promote cell cycle arrest by inducing cyclin-
dependent kinase (CDK) inhibitor p21 [24,25], cyclin D3 [26] and
retinoblastoma (Rb) tumor suppression protein [27,28], all of
which have important functions towards cell cycle withdrawal.
Interestingly, overexpression of MyoD is able to promote
myoblasts to differentiate, while by overexpression of Myf5 fail
to differentiate [23]. MyoD is also expressed in myotubes and
collaborates with myogenin to regulate the expression of genes
necessary for terminal differentiation [29].
Myogenin and Myf6 are expressed upon the differentiation of
myoblasts to multinucleated myotubes [22,30,31,32]. Myogenin is
essential during differentiation. Mice lacking the myogenin gene
die at birth due to severe skeletal muscle deficiency, as myoblasts
are unable to fuse into multinucleated myofibers [33]. Further-
more, MyoD and Myf5 are unable to substitute myogenin’s
functions during differentiation [34]. Mice lacking the myogenin
gene express normal levels of MyoD and Myf5 [33].
Here we show that down-regulation of endogenous myogenin
gene expression in terminally differentiated mouse muscle cells
causes cleavage of myotubes into mononucleated cells and entry to
the cell cycle through down-regulation of MyoD, in two different
pathways. These results reveal yet another important role for
myogenin which is to prevent reversal of muscle cell differentia-
tion.
Results
Reduction of terminally differentiated myotubes after
down-regulation of endogenous myogenin expression
As a first step to determine whether MRFs are needed to
maintain terminal muscle cell differentiation, terminally differen-
tiated cells were transfected with individual siRNAs, specific for
each of the four MRFs (MyoD, Myf5, myogenin, Myf6). C2C12
cells, which are suitable for in vitro differentiation were grown to
confluency and induced to become multinucleated myotubes,
prior to transfections. Following transfections, RNA analysis
revealed the expected and specific reduction of mRNA of all
MRFs (fig. 1A).
Transfections with individual siRNAs for each of the four MRFs
was repeated and left for four days in growth medium in order to
determine whether down-regulation of MRFs could have any
effect on myotubes. Those cultures which expressed reduced
endogenous myogenin had significantly less myotubes (fig. 1B).
SiRNA-Myogenin transfected myotubes exhibited a significantly
reduced number of myosin heavy chain (MHC) stained myotubes,
a terminally differentiation marker, compared to cells, which
expressed reduced endogenous levels of MyoD, Myf5 and Myf6
(fig. 1B). Fusion Index (FI), a way to measure muscle cell
differentiation was also found to be significantly lower (12%) in
cells transfected with myogenin siRNA, compared to cells
transfected with MyoD (89%), Myf6 (75%), Myf5 (73%) siRNA,
negative siRNA (97%) and untransfected myotubes (100%)
(fig. 1C).
Down-regulation of myogenin in terminally
differentiated muscle cells induces myotube cleavage
into active mononucleated product cells
As a result of the large reduction in myotubes, due to down-
regulation of endogenous myogenin, experiments were carried out
to investigate in more detail the mechanism by which this occurs.
The first experiments aimed at looking at the morphological
changes which occur in myotubes, following myogenin siRNA
transfections. After differentiation of myoblasts into multinucleated
myotubes, cells were transfected with myogenin siRNA. Myotubes
transfected with myogenin siRNA cleaved into mononucleated
cells almost 70 h after transfection, as seen by time-lapse
microscopy (fig. 2).
This finding indicates that the induced reduction of myogenin
endogenous levels in differentiated multinucleated myotubes
initiates a cellular mechanism, which results in the cleavage of
these cells into mononucleated product cells. Furthermore,
product cells obtained from the cleavage of multinucleated
myotubes expressed significantly reduced myogenin levels com-
pared to uncleaved myotubes which express normal myogenin
levels (fig. 3).
In order to investigate whether product cells, which arise from
the down-regulation of endogenous myogenin gene expression,
can reenter cell cycle, cells were stained with 5-ethynyl-29-
deoxyuridine (EdU). Cells which derived from the cleavage of
myotubes incorporated high levels of EdU (fig. 4), indicating that
these cells have active DNA replication.
Down-regulation of myogenin in terminally
differentiated myotubes reactivates cell cycle through
MyoD
Down-regulation of myogenin caused cleavage of terminally
differentiated myotubes into mononucleated product cells, which
can reenter into the cell cycle. As a next step, a series of molecular
experiments was carried out to reveal changes of important
molecules which are implicated in cell cycle activation and
differentiation of muscle cells. MyoD levels were lower in cells
transfected with myogenin siRNA than control cells, indicating
that down-regulation of myogenin may cause the endogenous
down-regulation of MyoD (fig. 5A, B). Similarly, Myf6 levels were
lower compared to control cells (fig. 5A, B). Interestingly, down-
regulation of endogenous myogenin levels caused an increase in
Myf5 levels, which may be due to a compensatory effect of the
MyoD decrease (fig. 5A, B). Several previous reports showed that
MyoD and Myf5 might compensate for each other [35]. Down-
regulation of myogenin caused also the induction of cyclins D1
and E2 which are both involved in the G1-S transition of the cell
cycle (fig. 5A, B) [36].
SiRNA-mediated down-regulation of MyoD in terminally
differentiated myotubes, on the other hand caused similar
molecular changes, as those seen in cells transfected with
myogenin siRNA. More specifically, reduction of endogenous
MyoD levels in terminally differentiated cells resulted in increases
of Myf5 (probably to compensate for MyoD reduction), cyclin D1
and E2 levels (fig. 5A, B).
Apart from the increase in MyoD levels, which was caused by
the down-regulation of endogenous Myf5, both Myf5 and Myf6
siRNAs had no molecular effects on molecules which are
implicated in muscle cell differentiation and the cell cycle.
These molecular results show that down-regulation of myogenin
gene expression of terminally differentiated cells alters gene
expression which is involved both in muscle cell differentiation
and the cell cycle. The decrease in MyoD and the subsequent
Myogenin Reverses Muscle Cell Differentiation
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differentiation, as seen by the cleavage of myotubes and the
creation of active mononucleated cells. The results also indicate
that down-regulation of myogenin leads cells to the cell cycle,
probably through the down-regulation of MyoD.
Cleavage of myotubes and cell cycle reactivation have
different pathways
Results so far showed that down-regulation of endogenous
myogenin levels caused the cleavage of myotubes into mononu-
cleated cells and lead cells into the cell cycle, probably through
down-regulation of MyoD.
In order to determine the way by which reduction of
myogenin drives cells to cleavage and cell cycle, terminally
differentiated myotubes were transfected with myogenin siRNA
in the presence of an adenovirus, expressing MyoD (AdMyoD).
The aim was to prevent cell cycle reactivation by preventing
MyoD levels from being reduced through myogenin down-
regulation. Overexpression of MyoD and down-regulation of
endogenous myogenin levels did not stop myotubes cleavage and
cellularisation (fig. 6A, B). No differences in their ability to
change morphologically into mononucleated cells were seen
compared to myotubes transfected only with myogenin siRNA
(fig. 6A).
In order to characterize molecularly the effect of overexpression
of MyoD in parallel with the down-regulation of myogenin, RNA
analysis was carried out for molecules which are implicated in
muscle cell differentiation and the cell cycle. Cells transfected with
AdMyoD and myogenin siRNA had reduced endogenous
myogenin RNA and protein levels and increased MyoD levels,
similar to those detected in control transfected cells (fig. 7A, B). As
a result of the repaired MyoD levels, no induction was observed in
cyclin D1 and E2 levels (fig. 7A, B). Overexpression of MyoD
successfully prevented cyclins from being induced from resting
levels. This result, in combination with the cellularisation seen in
cells transfected with AdMyoD and myogenin siRNA indicate that
down-regulation of myogenin can cause cell cycle reentry and
cleavage of myotubes into mononucleated cells possibly through
two different pathways (fig. 8). Overexpression of MyoD only was
also carried out in myotubes and showed increase in both MyoD
and myogenin endogenous levels (fig. 7A, B). It is well possible that
in the terminal differentiated state of myotubes, overexpression of
MyoD induces myogenin expression, as it has been shown by
others [37]. This does not happen in cells transfected also with
Figure 1. siRNA-mediated down-regulation of myogenin causes reduction of terminally differentiated myotubes. (A) Following
differentiation into myotubes, cells were transfected with myogenin, MyoD, Myf6 and Myf5 siRNAs and controls (d0). Growth medium was added to
cells two days later (d2) and left for two more days (d4). RNA analysis revealed a substantial reduction at the RNA levels of myogenin, MyoD, Myf6 and
Myf5, compared to controls (negative siRNA and control transfection) and untransfected C2C12 cells. GAPDH was used as an internal control. (B) MHC
immunostaining revealed a substantial reduction of myotubes in cells transfected with myogenin siRNA compared to cells transfected with MyoD,
Myf6, Myf5 and control cells (Scale, 200 mm). (C) Fusion Index was calculated from cells transfected with each siRNA and immunostained with MHC.
Fusion Index (FI) was defined as the number of nuclei present in myotubes in comparison over the total number of nuclei present in the observed
field. Data was selected from 10 different and randomly chosen microscopic fields. Cells transfected with myogenin siRNA showed significantly lower
FI (12%), compared to cells transfected with MyoD (89%), Myf6 (75%), Myf5 (73%), negative siRNA (97%), and untransfected cells set to 100.
doi:10.1371/journal.pone.0029896.g001
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PLoS ONE | www.plosone.org 3 January 2012 | Volume 7 | Issue 1 | e29896Figure 2. Myogenin siRNA transfection in terminally differentiated myotubes causes their cleavage into active mononucleated
cells. Following myotube differentiation, cells were transfected with myogenin siRNA. Growth medium was then added to the cells and placed for
time lapse microscopy. (I) (0 h), myotubes just after myogenin siRNA transfection. (0 h–68 h), uncleaved myotube (field 2) and cleaved myotubes
(field 1) after myogenin siRNA transfection (Scale, 250 mm). (II) Myotube in field 1 in higher magnification from 0 h–68 h displayed significant
Myogenin Reverses Muscle Cell Differentiation
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of myogenin initiates reversal of differentiation first and does not
allow induction of its expression by the overexpressed MyoD.
Furthermore, cells which originated from the cleavage of
myotubes transfected with myogenin siRNA, showed high EdU
incorporation: almost all cleaved cells exhibited EdU incorpora-
tion (fig. 7C).
Discussion
During this work, an attempt was made to investigate the role of
the four MRFs in maintaining terminal differentiation in muscle
cells. Down-regulation of myogenin in C2C12 mouse myotubes
caused cleavage into mononucleated cells and entry into the cell
cycle through down-regulation of MyoD. Results from this study
show also that down-regulation of myogenin causes cleavage of
myotubes through a mechanism which is independent of the cell
cycle reentry.
MRFs and especially myogenin were shown to regulate fusion of
myoblasts into multinucleated muscle cells. In myogenin-null
mice, very few myoblasts are able to fuse even when these
myoblasts are specified and position correctly in order to fuse
[38,39]. In vivo, targeted mutation in the myogenin gene caused the
severe reduction of all skeletal muscle, showing its importance
towards skeletal muscle development [33]. The fusion of myoblasts
is one of the key steps of muscle cell differentiation. Myogenin,
MyoD and Myf5 were shown to express in fusing myoblasts, with
each having as targets a distinct subset on muscle specific genes at
the on-set of fusion. Downregulation of these MRFs during fusion
period showed that particularly myogenin significantly inhibited
the fusion of myoblasts [40]. Our experiments show that down-
regulation of myogenin in terminally differentiated myotubes
induced cleavage of multinucleated myotubes into mononucleated
cells, the opposite of fusion of myoblasts. This is an important
finding with respect to the function of myogenin in myoblast
fusion. Regarding the reversal of muscle cell differentiation, it is a
novel finding that myogenin down-regulation initiates an unknown
mechanism which results to the fragmentation of myotubes into
mononucleated cells. It would be very important to indentify this
pathway in future studies.
MyoD is one of the key transcription factors responsible for
the differentiation of muscle cells. One of the main actions of
MyoD is the withdrawal of myoblasts from the cell cycle, in
order to initiate myogenesis [41]. As a result, MyoD is highly
e x p r e s s e di nu n d i f f e r e n t i a t e dm u s c l ec e l l sa n dc o n t i n u e st ob e
active during muscle cell differentiation [42]. Myf6 is highly
expressed during the last stages of muscle cell differentiation and
is only detectable in mature myofibers [42]. Molecular analysis
performed in our study revealed that down-regulation of
myogenin in terminally differentiated muscle cells reduced both
MyoD and Myf6 levels. This seems to be supported from the
fact that down-regulation of myogenin caused the reversal of
differentiation. In contrast to these changes, Myf5 was
upregulated. This is probably due to the compensation
mechanism between MyoD and Myf5 [43]. Mice and muscle
cells lacking MyoD are viable and fertile showing significantly
Figure 3. Mononucleated muscle product cells have reduced myogenin levels. Following myogenin siRNA transfection in terminally
differentiated myotubes and time lapse microscopy for 68 h (fig. 2), cells were fixed and immunostained with a specific myogenin antibody (Scale,
200 mm). Magnification of the myotube in field 2 showed normal myogenin expression (cleavage was not detected as observed by time lapse in
fig. 2). Magnification of the mononucleated product cells in field 1 (after cleavage of myotubes as observed in fig. 2), showed significantly reduced
myogenin expression levels (Scale, 200 mm).
doi:10.1371/journal.pone.0029896.g003
morphological changes and cleavage. During 15 h–30 h, myotubes began to morphologically change (arrows indicate the movement of the nuclei
and the areas of possible cleavage). During 36 h–68 h, myotubes were completely cleaved into mononucleated cells (arrows indicate cleaved cells)
(Scale, 200 mm). (III) Myotube in field 2 in higher magnification from 0 h–68 h showed no signs of cleavage (Scale, 200 mm).
doi:10.1371/journal.pone.0029896.g002
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Myf5 reveal a complete absence of skeletal muscle [35]. These
findings suggest that either Myf5 or MyoD is required for the
determination of skeletal myoblasts.
Furthermore, our experiments reveal re-activation of cell cycle
as seen by DNA replication through EdU incorporation and the
upregulation of cyclin D1 and cyclin E2. These results point to a
mechanism whereby down-regulation of myogenin in terminally
differentiated muscle cells induces a process of reversal of
differentiation. As previously shown, down-regulation of myogenin
in myotubes induces the reduction of MyoD levels. By transfecting
these myotubes with an adenovirus expressing MyoD, endogenous
MyoD levels were brought back to normal. These myotubes were
able to cleave but re-entry to the cell cycle was not obtained.
Cyclin D1 and cyclin E2 levels were similar to those expressed by
normal differentiated myotubes. These results point to a
mechanism whereby myogenin down-regulation is responsible
for the cleavage of terminally differentiated myotubes into
mononucleated cells in a separate way from the cell cycle re-
entry. In support to these findings, mice expressing homozygous
mutated myogenin gene show major reduction in skeletal muscle.
In contrast, homozygous mutations of Myf5 or MyoD showed no
effect on skeletal muscles [33,45]. Moreover, myogenin is required
for myoblast fusion and differentiation but not for commitment to
the myogenic lineage [34].
Furthermore, cyclin D1 antagonizes the myogenic activity of
MyoD [46,47]. Cyclin E2 is highly activated during the G1 to S
phase progression, with significant effects on cell cycle activity and
Figure 4. Mononucleated muscle product cells are active in DNA synthesis. (A) Following myotube differentiation, cells were transfected
with myogenin siRNA. Growth medium was then added to the cells and placed for time lapse microscopy. 64 h after transfection with myogenin
siRNA, myotubes cleaved into mononucleated cells (arrows indicate cleaved cells). Cells were then stained with EdU. Cells which derived from the
cleavage of myotubes (indicated by arrows) incorporated high levels of EdU. (B) Following myotube differentiation, cells were transfected with
myogenin siRNA. Growth medium was then added to the cells. Following various incubation time points of transfected cells in growth medium, 10,
20, 40 and 60 hours, cells were then stained with EdU. The number of EdU-positive cleaved cells was counted in 5 random microscopic fields for each
time point (Scale, 200 mm).
doi:10.1371/journal.pone.0029896.g004
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DNA synthesis were found up-regulated. Interestingly, scientific
evidence supports the hypothesis that cyclin E2 is in close
proximity to cyclin D1. In the absence of cyclin D1, cyclin E2 was
found to functionally replace cyclin D1 [48].
Our work with RNA interference has revealed that down-
regulation of endogenous myogenin gene expression in muscle
cells can lead to reversal of muscle cell differentiation and the
creation of mononucleated cells. There is growing evidence from
published findings from several groups that it is possible to reverse
Figure 5. Myogenin and MyoD siRNA transfection in terminally differentiated myotubes reactivates cyclin D1 and cyclin E2. (A)
Myoblasts treated with Ara-C and induced to differentiate into multinucleated myotubes were transfected with myogenin, MyoD, Myf6 and Myf5
siRNAs and controls. After transfections, growth medium was added to cells prior to RNA analysis by RT/PCR analysis. Cells transfected with myogenin
siRNA revealed reduction at the RNA levels of myogenin, MyoD, Myf6 and increase of cyclinD1, cyclinE2 and Myf5 when compared to controls and
untransfected C2C12 cells. Cells transfected with MyoD siRNA revealed reduction of the RNA levels of MyoD and substantial increase of cyclinD1,
cyclinE2 and Myf5. Cells transfected with Myf6 siRNA revealed reduction of the RNA levels of Myf6. Cells transfected with Myf5 siRNA revealed
reduction of the RNA levels of Myf5 and substantial increase of MyoD. (B) Graphs of the RNA analysis. Values were obtained as ratios of the RNA of
interest over GAPDH internal control.
doi:10.1371/journal.pone.0029896.g005
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report is based on manipulating endogenous levels in order to
achieve reversal of differentiation.
Materials and Methods
Tissue culture
C2C12 mouse myoblasts (ECACC) were grown to confluency
under 5% CO2 at 37uC in growth medium (GM), DMEM
medium (Gibco) supplemented with 10% (v/v) fetal bovine serum
(FBS) (Gibco), 2 mM glutamine (Gibco) and penicillin-streptomy-
cin (100 mg/ml–100 U/ml) (Gibco). In order to differentiate, cells
were then switched to differentiation medium (DM), DMEM
supplemented with 2% horse serum (v/v) (Gibco), 2 mM
glutamine and penicillin-streptomycin (100 mg/ml–100 U/ml)
for 4 days. During the first two days of differentiation, cytosine
b-D-arabinofuranoside (Ara-C) (Sigma) (4 mg/ml) was included in
order to eliminate all possible undifferentiated myoblasts. Medium
was then replaced with fresh DM medium without Ara-C. Ara-C
purified myotubes contained more than 90% of nuclei. For siRNA
transfections on differentiated myotubes 100 pmol of each siRNA
(MyoD, myogenin, Myf6 and Myf5) (Invitrogen) in complex with
Figure 6. Overexpression of MyoD does not prevent cleavage of siRNA – myogenin myotubes. Myotubes were transfected with
myogenin siRNA only, myogenin siRNA co-transfected with an adenovirus expressing MyoD (AdMyoD), AdMyoD only and a negative siRNA co-
transfected with a control adenovirus (AdC) (d0). After transfections, growth medium was added to cells (d2) and left for two more days (d4). Cells
transfected with myogenin siRNA and myogenin siRNA co-transfected with AdMyoD showed similar reduction of myotubes compared to cells
transfected with AdMyoD and negative siRNA co-transfected with AdC (Scale, 200 mm). (B) Time-lapse microscopy of cells co-transfected with
myogenin siRNA and AdMyoD showed cleavage of myotubes into mononucleated cells (indicated by arrows) similar to the cells transfected with
myogenin siRNA only (fig. 2.) (Scale, 200 mm).
doi:10.1371/journal.pone.0029896.g006
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Optimem solution (Gibco) were incubated in myotubes for
6 hours. Transfection mix was then substituted with fresh GM
medium. The following day, cells were re-transfected with each
siRNA and transfection mix was again substituted with fresh GM
medium.
Figure 7. Cleavage of myotubes and cell cycle reactivation have different pathways. (A), (B) RT/PCR and protein analysis on cells co-
transfected with myogenin siRNA and AdMyoD showed normal MyoD levels compared to cells transfected with myogenin siRNA only which showed
significantly reduced MyoD levels. Cells co-transfected with myogenin siRNA and AdMyoD showed normal cyclin D1 and cyclin E2 levels compared to
cells transfected with myogenin siRNA only, which showed to be substantially increased. Cells co-transfected with negative siRNA and AdC revealed
similar levels of cyclin D1 and cyclin E2. Cells transfected with AdMyoD showed to some extent higher myogenin and MyoD levels compared to cells
co-transfected with negative siRNA and AdC. GAPDH was used as an internal control. (C) Myotubes transfected as described above were treated with
EdU and detected by immunofluorescence. Cells transfected with siRNA myogenin showed significantly high levels of EdU, compared to the cleaved
cells co-transfected with myogenin siRNA and AdMyoD. Cells transfected with AdMyoD only or negative siRNA co-transfected with AdC showed no
signs of cleavage.
doi:10.1371/journal.pone.0029896.g007
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Cells were incubated with various antibodies after siRNA
transfections and 0–3 days of growth medium incubation. Briefly,
cells were fixed in 4% paraformaldehyde in PBS for 20 min,
washed once with PBS and permeabilized with 0.2% Triton-X-
100 in PBS for 20 min. Cells were blocked with 1% BSA in PBS
for 10 min and then exposed to primary antibodies. Cells were
tested for MHC (1/200; MY32, Sigma) and myogenin (1/200;
Santa-Cruz) for 2 hours in a 37uC humidified incubator. The cells
were washed three times with PBS and then treated with a
secondary antibody (goat anti-mouse Texas Red; Jackson
Immunoresearch) for 1 hour at room temperature. Cells were
washed three times with PBS and observed with a Zeiss
AxioVision observer using Texas Red filters. Fusion Index (FI)
was calculated as the number of nuclei present in myotubes over
the total number of nuclei present in the observed field. Data was
selected from 10 different and randomly chosen microscopic fields.
Cell cycle studies
Myotubes transfected with myogenin siRNA and incubated in
GM for up to three days, were then supplemented with 5-ethynyl-
29-deoxyuridine (EdU) for 3 hours (following manufacturer’s
instructions) (Invitrogen). Cells were then fixed with 4%
paraformaldehyde in PBS for 20 min. Cells were washed twice
with 3% BSA in PBS, before and after permeabilization with 0.5%
Triton-X-100 in PBS for 20 min at room temperature. Cells were
then incubated for 30 min in a mixture containing Alexa fluor
647. Cells were then washed with PBS and observed under a
fluorescence microscope.
RNA analysis
Total RNA was extracted from transfected or untransfected
myotubes (Perfect RNAEukaryotic Mini kit, Eppendorf) and then
subjected to reverse transcription. For PCR, specific primers were
usedforthe analysisofexpression for the followingmolecules:MyoD
F5 9-GCCCGCGCTCCAACTGCTCTGAT-39,R5 9- CCTACG-
GTGGTGCGCCCTCTGC-39. Myogenin F 59-CATCCAGTA-
CATTG AGCGCCTA-39,R5 9-GAGCAAATGATCTCCTGG-
GTTG. Myf6 F 59-ATG GTACCCTATCCCGTTGC-39,R5 9-
TAGCTGCTTTCCGACGATCT-39.M y f 5F5 9-TGAAGGATG-
GACATGACGGACG-39,R 59-TTGTGTGCTCCGAAGGCTG-
CTA-39.C y c l i nD 1F5 9-GGCACCTGGATTGTTCTGCT-39,R
59-CAGCTTGC TAGGGAACTTGG-39.C y c l i nE 2F5 9-GGAA-
CCACAGATGAGGTC-39,R5 9-CG TAAGCAAACTCTTG-
GAG-39.G A P D HF5 9-TCATCATCTCCGCCCCTTCT-39,R
59- GAGGGGCCATCCACAGTCTT-39.
Experiments were repeated at least three times and gel bands
were measured using the Scion Image software.
Western blot
Cells were lysed using a protein lysis buffer including protease
inhibitor. 40–60 mg of protein extracts were incubated with
myogenin (1/200; BD), MyoD (1/300; Santa-Cruz), cyclin D1
(1/400; Abcam), cyclin E2 (1/200, Abcam) and GAPDH (1/2000;
Santa-Cruz) primary antibodies followed by incubation with goat
anti-mouse IgG or donkey anti-rabbit IgG secondary antibodies
conjugated to horseradish peroxidase (Santa-Cruz).
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